Allegations Of EU Notified Body Fees Having Escalated And Of Being Unpredictable
Executive Summary
US medtech companies are worried EU notified bodies have too much freedom over setting their fees, accusing them of lacking transparency and being inconsistent with what they charge. They also allege that notified body practices mean some products will miss the four-year grace period.